Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523168 · ClinicalTrials.gov registry record · NA
Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
A NA study of Coronary Microvascular Dysfunction, sponsored by Amir Lerman.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04523168: Completed NA study of Coronary Microvascular Dysfunction, sponsored by Amir Lerman.
NCT04523168 is a NA study of Coronary Microvascular Dysfunction that has completed, run by Amir Lerman. The registered enrollment target is 30 participants, below the 268-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04523168, a NA study of Coronary Microvascular Dysfunction, has completed, sponsored by Amir Lerman.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary microvascular dysfunction.
Primary Outcome
Coronary flow reserve is calculated as the ratio of hyperemic or maximal flow down a coronary vessel to the resting coronary blood flow.
Conditions Studied
Interventions
- DEVICE The Neovasc Reducer™ System
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2023-07-28 |
| Phase | NA |
What the finished NCT04523168 record still lists
NCT04523168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 268-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Coronary Microvascular Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which The Neovasc Reducer™ System is the first listed.
NCT04523168 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04523168 about?
NCT04523168 is a clinical study titled "Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction". This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary microvascular dysfunction.
What is the current status of trial NCT04523168?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-28. Estimated completion is 2023-07-28.
What conditions does trial NCT04523168 study?
This clinical trial studies the following conditions: Coronary Microvascular Dysfunction.
What interventions are being tested in trial NCT04523168?
The interventions under investigation include: The Neovasc Reducer™ System (DEVICE).
Who is sponsoring clinical trial NCT04523168?
This trial is sponsored by Amir Lerman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04523168 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Microvascular Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
RECRUITING
-
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
RECRUITING
-
Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution
RECRUITING
-
Coronary Microvascular Disease (CMD) Registry
RECRUITING
-
The DISCOVER INOCA Prospective Multi-center Registry
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI